FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer
Study Information
Alliance Study ID: A021302
NCT Study ID (ClinicalTrials.gov): NCT02485834
Alliance Committee: Gastrointestinal Cancer
Disease or Cancer Type: Gastrointestinal Cancers – Pancreatic / Gastric / Esophageal / Liver / Biliary
Alliance Study Chair: Manish Shah, MD
Status: TERMINATED
Study Description
This randomized phase II trial studies how well fludeoxyglucose F-18 (FDG)/positron emission tomography (PET) directed treatment improves response in patients with stomach or gastroesophageal junction cancer that has not spread past the stomach and is not responding to the usual treatment. PET scans are a different way to take pictures of cancer and can be used to look at how much energy (such as glucose) is being used by the cancer. Using PET scans early to monitor the success of treatment may allow doctors to measure response and change treatment accordingly.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information